Coagulation

A first-grade teacher with steroid-dependent ITP wants the bleeding fixed without foreclosing a pregnancy she and her husband are planning for next year — and the two second-line options carry opposite timing risks for that plan.

A patient with prosthetic-valve MRSA endocarditis develops a textbook drug-dependent platelet crash on vancomycin — the drug his infection most wants, and the one his blood can no longer tolerate.

A woman presenting with acute immune TTP has a healing extraction socket that makes the drug most likely to save her platelets also the drug most likely to make her mouth bleed.

A cirrhotic patient awaiting liver transplant needs hernia repair before it strangulates — but the drug that would spare him a platelet transfusion, and the alloimmunization risk that comes with one, needs more runway than his calendar wants to give it.

One patient's von Willebrand disease responds to a nasal spray; the other's gets worse on it — the subtype, not the surgery, is what actually decides the regimen.

A boy's low-titer factor VIII inhibitor could plausibly still be eradicated with immune tolerance induction — but that path runs through the exact kind of daily infusion burden his family has already spent two years trying to escape.

An otherwise-independent 79-year-old with a new, spontaneous factor VIII inhibitor needs immunosuppression to survive it — and the regimen with the better remission odds in the registry data is also the one most likely to cost him that independence.

A septic patient's coagulation panel reads like a transfusion emergency, but nothing on his skin or in his output backs that up — the team has to decide whether to treat the labs or the patient.

Her factor XI level alone would suggest a mild, low-risk deficiency — but factor XI bleeding famously doesn't track its own lab value, and her family's actual bleeding history says something the number can't.

Standard-dose aspirin and prophylactic heparin already failed her once, in a pregnancy that ended in the second trimester — and the guideline she's being treated under wasn't built for someone who's already proven it isn't enough.

His platelet count and the timeline both point straight at heparin-induced thrombocytopenia — but the drug most doctors reach for first clears through a liver that his own labs say isn't working the way it should.

Two major cancer-VTE trials of two different DOACs reached opposite-looking conclusions about GI bleeding risk — and the drug he actually gets should depend on which trial's population he really resembles, not on habit.

Cascade testing after her sister's unprovoked pulmonary embolism found the same mutation in her — and now she wants to know what, if anything, a healthy person is actually supposed to do with that information.

His DVT looks like a textbook travel-provoked clot until the thrombophilia panel comes back positive — and the guidelines were never built to say clearly which fact should decide how long he stays on a blood thinner.

His illness started the way Shiga-toxin HUS is supposed to start — but it isn't behaving the way Shiga-toxin HUS is supposed to behave, and the test that would settle it takes weeks he may not have.

He has exactly one chance at hemophilia B gene therapy — re-dosing isn't possible if it doesn't take — and a low but detectable anti-AAV5 antibody titer means nobody can promise this is the try that works.

The guideline answer for reversing his warfarin is not actually in question — what's in question is whether a small rural hospital's pharmacy can produce it fast enough to matter.

Finding the cause of her portal vein clot should have made the decision easier — instead, discovering an occult blood cancer underneath it turned a finite-duration question into one about whether it's ever safe to stop.